Formulation and Process Optimization of Cinnarizine Fast-Release Tablets - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Formulation and Process Optimization of Cinnarizine Fast-Release Tablets
The authors prepared granules containing cinnarizine using polyethylene glycol 6000 as a melting binder and lactose monohydrate as hydrophilic filler. The effects of binder concentration and size were studied.


Pharmaceutical Technology
Volume 33, Issue 8, pp. 53-59

Results and discussion


Table I: Experimental conditions used to study the effect of binder and process parameters.
DSC analysis. DSC curves obtained for powdered CNZ, lactose monohydrate, PEG 6000, and granules prepared by melt granulation are shown in Figure 2. Pure powdered CNZ exhibited a melting endotherm at 125.54 °C. DSC scans of lactose monohydrate and PEG 6000 showed single sharp endotherms at 154.65 and 69.08 °C, respectively, due to melting of both compounds.


Figure 3: Size distribution of granules prepared with various binder concentrations. (FIGURE IS COURTESY OF THE AUTHORS)
DSC thermograms of granules of CNZ, lactose monohydrate, and PEG 6000 showed an absence of CNZ and the presence of sharp endothermic peaks because of the melting of PEG 6000 and lactose monohydrate. This complete absence of CNZ peak indicates that CNZ is present as amorphous or as a solid solution inside the PEG matrix.


Figure 4: In vitro dissolution of granules prepared with various binder concentrations. (FIGURE IS COURTESY OF THE AUTHORS)
Effect of binder concentration. The various granulation batches prepared to study the effect of binder concentration are listed in Table I (batches M1–M3). Figure 3 shows the particle-size distributions of the granules prepared using various binder concentrations. Ungranulated fines decreased as the concentration of PEG increased from 10.0% to 20.0% (w/w). Particle-size distribution widened as the PEG content of the feed increased from 10.0% to 20.0% (w/w). When granulation was attempted with a PEG content of 25% (w/w), slurry was produced (i.e., the system was over-wetted and defluidized). In Figure 3, there is evidence of the emergence of overwetting in the granulation with a feed with PEG content of 20 % (w/w).


Figure 5: Size distribution of granules prepared with binder of various particle sizes. (FIGURE IS COURTESY OF THE AUTHORS)
The in vitro dissolution rate of all prepared granulates increased compared with that of the drug alone. This increase is a result of the higher hydrophilic character of the systems due to the carriers and the slight reduction of CNZ crystallinity (see Figure 4). No significant in vitro dissolution differences were attested among the granules prepared using various concentrations of the binder.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
18%
To all process for new products only
13%
To select process for new products only
22%
To select processes for both new and legacy products
22%
Do not use QbD
24%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Inadequate Access to Medicines Puts EU at Risk
FDA Offers Insight on QbD for Modified-Release Products
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
FindPharma Custom Search
Source: Pharmaceutical Technology,
Click here